The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 

AnergiX.RA Corixa.

Corixa (formerly Anergen), in collaboration with Organon, is developing AnergiX.RA, a complex of solubilized HLA DRB1-0401(a) together with a specific peptide from the human cartilage glycoprotein HCgp39, for the potential treatment of rheumatoid arthritis (RA) [307156]. Phase I/II trials were completed in April 2000 and the final results from the randomized, blinded, placebo-controlled dose-escalation study are expected later this year [363409]. The product utilizes Anergen's AnergiX technology, and combines an MHC-derived protein with an Organon autoantigen peptide, derived from myelin basic protein and involved in the development of RA [212659,363409]. Engagement of T-cell receptors with AnergiX.RA induces apoptosis in autoreactive T-cells [227421]. Researchers at Organon identified the central component in AnergiX.RA; results from preclinical studies identifying this target protein were published in June 1997 in Arthritis & Rheumatism. Researchers demonstrated that HC (human cartilage) gp39 is recognized by T-cells from RA patients and has the potential to block arthritis in the mouse model [248543,354821].[1]

References

  1. AnergiX.RA Corixa. Prokaeva, T. Current opinion in investigational drugs (London, England : 2000) (2000) [Pubmed]
 
WikiGenes - Universities